Century Therapeutics Inc (IPSC)
Century Therapeutics is a biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with unmet medical need. Co.'s primary product candidate, CNTY-101, is an allogeneic, chimeric antigen receptors (CAR)-induce pluripotent stem cell-derived (iPSC-derived) natural killer (iNK) cell therapy that has been engineered to express CD19 CAR, soluble IL-15, an epidermal growth factor receptor safety switch, and also contains gene edits needed to incorporate Allo-Evasion™ technology. CNTY-103 is Co.'s main product candidate targeting a solid tumor.
IPSC SEC Filing Email Alerts Service
| Company Name: |
Century Therapeutics Inc |
| Website: |
www.centurytx.com |
| Sector: |
Biotechnology |
| Number of ETFs Holding IPSC: |
13 |
| Total Market Value Held by ETFs: |
$5.84M |
| Total Market Capitalization: |
$197.00M |
| % of Market Cap. Held by ETFs: |
2.96% |
|
|
May 5, 2024 • 9:00 PM Eastern
Strong Buy (3.71 out of 4)
68th percentile
|
|
Free IPSC Email Alerts:
